| Aug 6 |
When Product Launches Struggle, Biotech Investors Reward Cost Cuts
|
| Aug 6 |
Q2 2024 Biomarin Pharmaceutical Inc Earnings Call
|
| Aug 6 |
BioMarin Pharmaceutical Reports Strong Q2 Driven by Voxzogo Sales, RBC Says
|
| Aug 6 |
BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View
|
| Aug 6 |
BioMarin pares Roctavian spending as it narrows sales focus
|
| Aug 6 |
BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript
|
| Aug 5 |
BioMarin (BMRN) Reports Q2 Earnings: What Key Metrics Have to Say
|
| Aug 5 |
BioMarin to focus Roctavian efforts on US, Germany, Italy
|
| Aug 5 |
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
|
| Aug 5 |
BioMarin raises 2024 guidance for revenue, non-GAAP EPS
|
